TY - JOUR AU - Huang, Lei AU - Balavarca, Yesilda AU - van der Geest, Lydia AU - Lemmens, Valery AU - Van Eycken, Liesbet AU - De Schutter, Harlinde AU - Johannesen, Tom B AU - Zadnik, Vesna AU - Primic-Žakelj, Maja AU - Mägi, Margit AU - Grützmann, Robert AU - Besselink, Marc G AU - Schrotz-King, Petra AU - Brenner, Hermann AU - Jansen, Lina TI - Development and validation of a prognostic model to predict the prognosis of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma: a large international population-based cohort study.3 JO - BMC medicine VL - 17 IS - 1 SN - 1741-7015 CY - Heidelberg [u.a.] PB - Springer M1 - DKFZ-2019-00767 SP - 66 PY - 2019 AB - Pancreatic cancer (PaC) remains extremely lethal worldwide even after resection. PaC resection rates are low, making prognostic studies in resected PaC difficult. This large international population-based study aimed at exploring factors associated with survival in patients with resected TNM stage I-II PaC receiving chemotherapy and at developing and internationally validating a survival-predicting model.Data of stage I-II PaC patients resected and receiving chemotherapy in 2003-2014 were obtained from the national cancer registries of Belgium, the Netherlands, Slovenia, and Norway, and the US Surveillance, Epidemiology, and End Results (SEER)-18 Program. Multivariable Cox proportional hazards models were constructed to investigate the associations of patient and tumor characteristics with overall survival, and analysis was performed in each country respectively without pooling. Prognostic factors remaining after backward selection in SEER-18 were used to build a nomogram, which was subjected to bootstrap internal validation and external validation using the European datasets.A total of 11,837 resected PaC patients were analyzed, with median survival time of 18-23 months and 3-year survival rates of 21-31 LB - PUB:(DE-HGF)16 C6 - pmid:30905320 DO - DOI:10.1186/s12916-019-1304-y UR - https://inrepo02.dkfz.de/record/143168 ER -